23andMe
Anne Wojcicki
"Restructuring amid business decline"
Anne Wojcicki
23andMe, a biotech company led by CEO Anne Wojcicki, has announced layoffs affecting 320 employees, which represents 40% of its workforce. The company cites "restructuring amid business decline" as the reason for these cuts, yet it has recently invested $90 million in AI, raising questions about the sustainability of its business model and the true motivations behind the layoffs.
| Headcount affected | 320 |
|---|---|
| Workforce % | 40% |
| Company | 23andMe |
| CEO | Anne Wojcicki |
| Geography | United States |
| Source | 23andMe cuts 40% of staff in restructuring |
Loading stock timeline…